Results 231 to 240 of about 119,169 (307)

Do Asian patients with HCC derive greater benefit from anti-PD-L1 plus anti-CTLA-4 therapy? [PDF]

Hepatobiliary Surg Nutr
Ono A, Hayes CN, Tsuge M, Oka S.
europepmc   +1 more source

Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B‐Cell Lymphomas Treated With Rituximab

Immunology, EarlyView.
Eight percent of this cohort of patients had a latent Neoehrlichia mikurensis infection. It was only the latently infected patients who had N. mikurensis‐specific T cells, not the matched B‐cell lymphoma patients without the infection. The T‐cell responses of latently infected patients included perforin‐expressing Th1 and CD8+ T cells that upregulated ...
Linda Wass, Catharina Lewerin, Daniel Jaén‐Luchoro, Christine Lingblom, Christine Wennerås   +4 more
wiley   +1 more source

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. [PDF]

J Immunother Cancer
Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A, Stebbing J, Joshi B, Bourdelais S, Delepine C, Chand D, Wu W, Johnson B, Grossman JE, O'Day SJ, Matulonis UA, Gordon MS.   +20 more
europepmc   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

<i>CTLA-4</i> +6230G>A polymorphism and its impact on CTLA-4 level and risk of hepatocellular carcinoma: A case-control study in Batak patients with chronic hepatitis B. [PDF]

Narra J
Darmadi D, Rey I, Lubis M, Lindarto D, Muzasti RA.   +4 more
europepmc   +1 more source

Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma. [PDF]

JCI Insight
Marks KE, Horisberger A, Elahee M, Adejoorin IA, Ghosh N, Postow M, Donlin L, Bass AR, Rao DA.   +8 more
europepmc   +1 more source

Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for up to 80% of all cases. Most patients present at an advanced stage and are unsuitable for curative treatments. In the past 5 years, immunotherapy combination has superseded tyrosine kinase inhibitors (TKI) as the standard first‐line therapy for ...
Landon L. Chan, Kallista O. K. Chan, Stephen L. Chan   +2 more
wiley   +1 more source

pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies. [PDF]

Proc Natl Acad Sci U S A
Zhang M, Li J, Yan K, Zhou H, Mei S, Wang B, Li D, Du X, Liu M, Zhang P, Fields JK, Ye L, Zheng P, Liu Y, Lenardo MJ, Zhang Y.   +15 more
europepmc   +1 more source

Immune Evasion of Helicobacter pylori and Extra‐Gastric Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Helicobacter pylori (H. pylori) is a group 1 gastric carcinogen that plays a significant role in extra‐gastric digestive system cancers. H. pylori disrupts host cell homeostasis through expression of virulence factors leading to immune evasion as well as persistent gastric mucosal colonization. H. pylori infection has been shown to play a role
Evren Doruk Engin, Ayse Basak Engin, Atilla Engin   +2 more
wiley   +1 more source

Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy. [PDF]

J Transl Med
Weidhaas JB, McGreevy KM, Marco N, Sundahl N, Cabanski CR, Spencer C, LaVallee T, Ost P, Telesca D.   +8 more
europepmc   +1 more source